Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 127 participants.

Also called NCT01820078

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 127 participants (enrolled count) (from the registry)
Sponsor
Fundación Renal Iñigo Alvarez De Toledo (from the registry)
Registry
  • NCT NCT01820078
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01820078. Randomized; no masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2013-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)
Acronym
PALIFE
Condition
Chronic Kidney Disease, Unspecified
Intervention (Drug)
Experimental arm
Intervention (Other)
Comparator Arm
Lead sponsor
Fundación Renal Iñigo Alvarez De Toledo (class: other)
Collaborator
Effice Servicios Para la Investigacion S.L. (class: industry)

Record details

Record id
cardio:ct-nct01820078
Content hash
a1cbcbea490a99e40a558ce6ccbb7c09a06d3ba2b28b99a92ce7fbb03abd4a18